Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
CVL-871
Другие языки:

    CVL-871

    Подписчиков: 0, рейтинг: 0
    CVL-871
    Clinical data
    Routes of
    administration    		 Oral administration
    Drug class Dopamine receptor agonist

    CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It was originated by Pfizer and is under development by Cerevel Therapeutics. CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors. It is taken via oral administration. As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.

    See also

    External links




    Новое сообщение